glp-1 and ulcerative colitis The alleviating effect mechanism of on Ulcerative colitis and GLP-1 medications

It was described that the number of normoalbuminuric DKD patients has increased over the past two decades, as well as the prevalence of eGFR decline, meaning that the occurrence of DKD is stable and steadily on the rise [46]

While the term specifically references Ozempic, it can happen with any form of accelerated weight loss, whether from medication, surgery, or extreme dieting

Findings: On the 10 GLP-1 receptor agonists included in the cohort, drug manufacturers listed with the FDA a median of 19.5 patents (interquartile range [IQR]: 9.0-25.8) per product, including a median of 17 patents (IRQ: 8.3-22.8) filed before FDA approval and 1.5 (IQR: 0-2.8) filed after FDA approval

For most patients on GLP-1s, the question in the back of their minds is: Do I need to stay on this forever? Even after they've reached their weight loss goals, they worry that once they stop the medication, the hunger, weight gain, and food noise will come right back

The findings demonstrated a significant reduction in all-cause mortality, with an odds ratio of 0.49 (95% CI [0.410.60]